The Computational Drug Repositioning without Negative Sampling
Computational drug repositioning technology is an effective tool to accelerate drug development. Although this technique has been widely used and successful in recent decades, many existing models still suffer from multiple drawbacks such as the massive number of unvalidated drug-disease associations and the inner product. The limitations of these works are mainly due to the following two reasons: firstly, previous works used negative sampling techniques to treat unvalidated drug-disease associations as negative samples, which is invalid in real-world settings; secondly, the inner product cannot fully take into account the feature information contained in the latent factor of drug and disease. In this paper, we propose a novel PUON framework for addressing the above deficiencies, which models the risk estimator of computational drug repositioning only using validated (Positive) and unvalidated (Unlabelled) drug-disease associations without employing negative sampling techniques. The PUON also proposed an Outer Neighborhood-based classifier for modeling the cross-feature information of the latent facotor. For a comprehensive comparison, we considered 8 popular baselines. Extensive experiments in four real-world datasets showed that PUON model achieved the best performance based on 6 evaluation metrics.
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
Self-supervised Learning for Label Sparsity in Computational Drug Repositioning
The computational drug repositioning aims to discover new uses for marketed drugs, which can accelerate the drug development process and play an important role in the existing drug discovery system. However, the number o…
Data AugmentationDrug DiscoverySelf-Supervised LearningDeepDR: an integrated deep-learning model web server for drug repositioning
Background: Identifying new indications for approved drugs is a complex and time-consuming process that requires extensive knowledge of pharmacology, clinical data, and advanced computational methods. Recently, deep lear…
The Neural Metric Factorization for Computational Drug Repositioning
Computational drug repositioning aims to discover new therapeutic diseases for marketed drugs and has the advantages of low cost, short development cycle, and high controllability compared to traditional drug development…
Common Sense ReasoningDrug DiscoveryTurning genome-wide association study findings into opportunities for drug repositioning
Drug development is a very costly and lengthy process, while repositioned or repurposed drugs could be brought into clinical practice within a shorter time-frame and at a much reduced cost. The past decade has observed a…
Drug DiscoveryLearning a Patent-Informed Biomedical Knowledge Graph Reveals Technological Potential of Drug Repositioning Candidates
Drug repositioning-a promising strategy for discovering new therapeutic uses for existing drugs-has been increasingly explored in the computational science literature using biomedical databases. However, the technologica…
Graph Embedding